Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

The role of SAM-dependent internal m7G modification of LINC01252 in the progression of hepatocellular carcinoma

Dysregulation of long non-coding RNAs (lncRNAs) plays a significant role in the progression of hepatocellular carcinoma (HCC), yet many underlying mechanisms remain elusive. Recent studies have highlighted the critical importance of internal N 7 -methylguanosine (m 7 G) modifications in influencing RNA expression and function. In this study, we identified LINC01252, a poorly characterized lncRNA, through analyses of GEO datasets and the TCGA cohort. Notably, LINC01252 is downregulated in HCC tissues and is associated with prognostic outcomes, although the predictive value of a nomogram based on LINC01252 expression characteristics appears to be limited. Our results indicate that LINC01252 effectively inhibits tumorigenic behaviors in HCC and exerts its effects by targeting the oncogene NUPR1. Mechanistically, LINC01252 acts as an intranuclear lncRNA that binds to the NUPR1 promoter through Hoogsteen pairing, consequently inhibiting its transcriptional activity. Additionally, the internal m 7 G modification level of LINC01252 directly influences its RNA stability, contingent upon sufficient concentrations of S-adenosylmethionine (SAM), which is necessary for the activity of its key modifying enzymes, METTL1 and WDR4. Thus, LINC01252’s m 7 G modification and expression are SAM-dependent in the context of HCC. Furthermore, LINC01252 can also suppress WDR4 transcription by binding to its promoter through the same mechanism, thus inhibiting HCC progression. Our findings suggest that LINC01252 functions as a SAM-dependent, m 7 G-related lncRNA, acting as a transcriptional repressor of NUPR1 and WDR4, while establishing a negative feedback loop between LINC01252 and WDR4. However, the potential of LINC01252 as a clinical biomarker still requires further investigation.

Xue-Han Zhao, Min Shi, Li Zhao et al. · 0 citations
Review Aug 2026

USP2 in cancer: a double-edged sword and therapeutic target.

Ubiquitin-specific protease 2 (USP2), a pivotal member of the deubiquitinating enzyme family, has emerged as a critical but context-dependent regulator in cancer, exhibiting paradoxical tumor-suppressive and oncogenic functions. This duality is governed by its ability to stabilize specific substrate proteins, thereby modulating central signaling hubs including the p53, Wnt/β-catenin, PI3K/Akt, and cell cycle networks. Through these axes, USP2 profoundly influences hallmark cancer phenotypes such as sustained proliferation, metabolic reprogramming, metastatic progression, immune evasion, and therapy resistance. This review systematically synthesizes the mechanistic roles of USP2 across various cancers, highlighting its function as a double-edged sword. We detail how specific interactions between USP2 and its substrates dictate its pro-tumorigenic or anti-tumorigenic outcomes, depending on the tissue and microenvironment. Furthermore, we comprehensively evaluate the landscape of emerging USP2 inhibitors, discussing their therapeutic potential and the significant challenges posed by USP2's functional duality, substrate promiscuity, and isoform diversity. Targeting USP2 presents a promising yet intricate avenue for cancer therapy, necessitating future research focused on patient stratification, combination strategies, and the development of context-specific inhibitors.

Peng Hao, Jiale Wan, Zhangyu Guo et al. · 0 citations